

Gilles Paintaud

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7256389/gilles-paintaud-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

133 papers	5,023 citations	35 h-index	68 g-index
144 ext. papers	5,692 ext. citations	4.9 avg, IF	5 L-index

#	Paper	IF	Citations
133	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	0
132	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). <i>European Journal of Cancer</i> , 2021 , 158, 169-180	7.5	2
131	A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations. <i>Bioanalysis</i> , 2021 , 13, 565-574	2.1	0
130	Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	
129	Panitumumab and cetuximab affect differently miRNA expression in colorectal cancer cells. <i>Biomarkers in Medicine</i> , 2021 , 15, 685-696	2.3	0
128	Letter to Dreesen et al. on their article "Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease"-A comprehensive review of infliximab population pharmacokinetic modelling publications. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1594-1595	3.8	0
127	Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2236-2246	3.8	3
126	Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 210-219	6.1	0
125	Infliximab Treatment Does Not Lead to Full TNF- α Inhibition: A Target-Mediated Drug Disposition Model. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
124	Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1069	27.4	
123	Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). <i>Oncotarget</i> , 2020 , 9, 1848058	7.2	3
122	Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. <i>RMD Open</i> , 2020 , 6,	5.9	21
121	Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study. <i>EClinicalMedicine</i> , 2020 , 28, 100566	11.3	1
120	Kinetic modelling of myocardial necrosis biomarkers offers an easier, reliable and more acceptable assessment of infarct size. <i>Scientific Reports</i> , 2020 , 10, 13597	4.9	1
119	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 519-530	6.2	5
118	Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 37-49	6.2	13
117	CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2747-2758	3.8	8

116	17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia 2019 , 7, 22		8
115	Intra-tracheal amikacin spray delivery in healthy mechanically ventilated piglets. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019 , 57, 101807	3.5	3
114	Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2002-2010	3.8	10
113	In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration. <i>Journal of Controlled Release</i> , 2019 , 303, 24-33	11.7	11
112	Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 169-187	6.2	20
111	A successful compartmental approach for the treatment of breast cancer brain metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 573-580	3.5	0
110	A novel way to manage trastuzumab cardiotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 791-796	3.5	0
109	Development and validation of an ELISA to study panitumumab pharmacokinetics. <i>Bioanalysis</i> , 2018 , 10, 205-214	2.1	3
108	Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab. <i>European Journal of Cancer</i> , 2018 , 92, 119-120	7.5	3
107	Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1173-1184	6.2	10
106	Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis: An Opportunity to Improve the Efficiency of Anti-VEGF Therapy in Fighting Metastatic Colorectal Cancer?. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e109-e113 ²¹	3.8	11
105	Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot Study. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1745-1754	4.5	7
104	Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 165-177	6.2	17
103	Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1773-1781	3.8	23
102	Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. <i>Blood</i> , 2017 , 129, 2616-2623	2.2	57
101	Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 360-363	3.2	7
100	Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 339-343	3.2	9
99	Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 322-326	3.2	18

98	Immunoassays for Measuring Serum Concentrations of Monoclonal Antibodies and Anti-biopharmaceutical Antibodies in Patients. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 316-321	3.2	14
97	Revisiting myocardial necrosis biomarkers: assessment of the effect of conditioning therapies on infarct size by kinetic modelling. <i>Scientific Reports</i> , 2017 , 7, 10709	4.9	12
96	Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. <i>Bioanalysis</i> , 2017 , 9, 1227-1235	2.1	7
95	A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. <i>BMC Cancer</i> , 2017 , 17, 220	4.8	11
94	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 635-647	6.2	16
93	Concentration-Response Relationship of Hearing Impairment Caused by Quinine and Salicylate: Pharmacological Similarities but Different Molecular Mechanisms. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017 , 120, 5-13	3.1	6
92	Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 108-113	9.5	18
91	Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF- α Antibodies after a Single Injection in Mice. <i>Journal of Immunology</i> , 2017 , 199, 418-424	5.3	13
90	Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study. <i>American Journal of Hematology</i> , 2016 , 91, 1246-1251	7.1	37
89	Gota et al. on their article "the pharmacokinetics of Reditux α biosimilar of rituximab". <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 1317-1318	3.5	2
88	Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 567-72	3.2	12
87	CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. <i>Transplant International</i> , 2016 , 29, 184-95	3	5
86	Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1381-1394	6.2	34
85	A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 253-5	2.8	9
84	IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding. <i>Journal of Immunology</i> , 2016 , 196, 607-13	5.3	41
83	Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 941-8	3.8	22
82	The underlying inflammatory chronic disease influences infliximab pharmacokinetics. <i>MAbs</i> , 2016 , 8, 1407-1416	6.6	37
81	Pharmacokinetics of adalimumab in Crohn's disease. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1155-7	2.8	24

80	Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 1107-23	6.2	72
79	Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review. <i>Acta Dermato-Venereologica</i> , 2015 , 95, 401-6	2.2	4
78	Suivi thérapeutique pharmacologique des anti-TNF- α au cours des spondyloarthrites. <i>Revue Du Rhumatisme Monographies</i> , 2015 , 82, 63-67	0	1
77	Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia. <i>MAbs</i> , 2015 , 7, 630-7	6.6	18
76	Development and validation of an enzyme-linked immunosorbent assay to measure adalimumab concentration. <i>Bioanalysis</i> , 2015 , 7, 1253-60	2.1	12
75	A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1541-2	2.8	12
74	F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumor necrosis factor- α antagonist, in rheumatoid arthritis: A prospective pilot study. <i>Joint Bone Spine</i> , 2015 , 82, 381-3	2.9	4
73	Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 286-97	3.8	51
72	Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. <i>Pharmacogenomics</i> , 2015 , 16, 2035-43	2.6	3
71	Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 551-62	6.2	43
70	Lung and serum teicoplanin concentration after aerosol and intravenous administration in a rat model. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2014 , 27, 306-12	3.8	6
69	Towards an individualised target concentration of adalimumab in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1428-9	2.4	21
68	Ranibizumab (Lucentis): a New Anti-Angiogenic Treatment in Ophthalmology 2014 , 1883-1898		
67	ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. <i>MAbs</i> , 2014 , 6, 794-9	6.6	35
66	Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1493-1502	21.7	89
65	Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 118-28	3.8	57
64	Influence of FcRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 26-34	1.9	9
63	Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 978-86	4.5	117

62	VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. <i>MABs</i> , 2014 , 6, 1638-48	6.6	23
61	Relationship Between Metabolic Tumor Volume and Rituximab Pharmacokinetic Parameters in Non-Hodgkin's Lymphoma. <i>Blood</i> , 2014 , 124, 3644-3644	2.2	
60	Very low residual concentrations of rituximab long after infusion still induce positive B-cell complement-dependent cytotoxicity-crossmatch. <i>Human Immunology</i> , 2013 , 74, 1616-8	2.3	12
59	Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 649-50	4.5	11
58	Influence of plasma exchange on rituximab pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 486-8	3.8	6
57	Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies. <i>MABs</i> , 2013 , 5, 614-9	6.6	36
56	Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 597-605	3.8	19
55	Successful treatment of post-transplant Epstein-Barr virus-related meningoencephalitis by intravenous rituximab monotherapy. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2063-5	1.9	4
54	Doit-on mesurer les concentrations sériques d'anti-TNF- α et/ou d'anticorps anti-médicament au cours de la polyarthrite rhumatoïde ?. <i>Revue Du Rhumatisme (Edition Française)</i> , 2012 , 79, 97-100	0.1	
53	Ex vivo study of bevacizumab transport through porcine nasal mucosa. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012 , 80, 465-9	5.7	33
52	Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. <i>Gastroenterology</i> , 2012 , 142, 63-70.e5; quiz e31	13.3	446
51	Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 55-65	3.8	40
50	Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 948-55	27.4	242
49	Monoclonal Antibodies for Therapeutic Use: Specific Characteristics of Clinical Development, Evaluation by the Agencies, and Long-term Monitoring of Safety. <i>Thérapie</i> , 2012 , 67, 329-37	3.8	2
48	Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R82	5.7	31
47	Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2011 , 13, R105	5.7	109
46	Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 411-6	3.2	23
45	The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. <i>Pharmaceutical Research</i> , 2011 , 28, 2147-56	4.5	48

44	Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 6329-37	12.9	77
43	Therapeutic antibodies in ophthalmology: old is new again. <i>MAbs</i> , 2010 , 2, 176-80	6.6	19
42	An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 647-52	3.2	28
41	Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need. <i>Therapie</i> , 2010 , 65, 373-7, 367-72	3.8	2
40	Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 232-6	3.2	51
39	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2009 , 68, 561-73	3.8	17
38	Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. <i>Gastroenterology</i> , 2009 , 137, 1628-40	13.3	403
37	Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009 , 11, R178	5.7	50
36	An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 597-601	3.2	30
35	Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. <i>Blood</i> , 2009 , 113, 3765-72	2.2	102
34	Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of FcγRIIIa genetic polymorphism. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 60-8	3.8	8
33	Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. <i>Gastroenterology</i> , 2008 , 134, 1861-8	13.3	390
32	Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4223-5	2.2	13
31	Infliximab pharmacokinetics in inflammatory bowel disease patients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 523-9	3.2	143
30	Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. <i>Intensive Care Medicine</i> , 2008 , 34, 755-62	14.5	43
29	Pharmacokinetics of rituximab and its clinical use: thought for the best use?. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 62, 43-52	7	97
28	Pharmacokinetics of bevacizumab in haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 975	4.3	25
27	Biotherapies: are they just like any other drugs?. <i>Therapie</i> , 2007 , 62, 229-39	3.8	1

26	Tumour Burden Influence on Individual Rituximab Exposure and Response: Pharmacokinetic - Pharmacodynamic Approach by Using a Syngenic Bioluminescent Murine Model.. <i>Blood</i> , 2007 , 110, 2347-2347	2.2	347
25	An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 169-74	3.2	86
24	No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 37-42	1.9	38
23	An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 442-4	1.7	5
22	Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0. <i>Fundamental and Clinical Pharmacology</i> , 2006 , 20, 91-6	3.1	3
21	Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies. <i>Blood</i> , 2005 , 106, 1503-4; author reply 1504-5	2.2	9
20	Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 34-42	6.1	29
19	Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5 Suppl 1, S37-47	5.4	87
18	Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2005 , 59, 18-27	3.8	21
17	Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. <i>Pharmaceutical Research</i> , 2005 , 22, 1432-7	4.5	146
16	Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. <i>Cancer Research</i> , 2004 , 64, 4664-9	10.1	356
15	Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 253-66	6.2	88
14	Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. <i>European Journal of Clinical Pharmacology</i> , 2002 , 57, 805-11	2.8	64
13	Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 71-80	6.2	49
12	Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection. <i>Therapeutic Drug Monitoring</i> , 2001 , 23, 679-88	3.2	16
11	Population pharmacokinetics of clomipramine, desmethylclomipramine, and hydroxylated metabolites in patients with depression receiving chronic treatment: model evaluation. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 701-11	3.2	10
10	On the assessment of drug metabolism by assays of codeine and its main metabolites. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 258-65	3.2	10
9	Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. <i>Fundamental and Clinical Pharmacology</i> , 1999 , 13, 595-604	3.1	32

8	The efficiency concept in pharmacodynamics. <i>Clinical Pharmacokinetics</i> , 1999 , 36, 375-89	6.2	19
7	The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide. <i>British Journal of Clinical Pharmacology</i> , 1998 , 45, 63-70	3.8	22
6	Methodological issues in pharmacokinetic-pharmacodynamic modelling. <i>Clinical Pharmacokinetics</i> , 1998 , 35, 151-66	6.2	33
5	Natriuretic efficiency of frusemide as a consequence of drug input rate. <i>British Journal of Clinical Pharmacology</i> , 1997 , 43, 481-91	3.8	11
4	Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 75-88	6.1	73
3	Effect of the transition from intravenous to oral dosing on cyclosporin-A trough concentrations in liver transplant patients. <i>Therapeutic Drug Monitoring</i> , 1996 , 18, 310-4	3.2	1
2	Modeling of the saturable time-constrained amoxicillin absorption in humans. <i>Pharmaceutical Research</i> , 1994 , 11, 1346-51	4.5	9
1	The concentration-effect relationship of quinine-induced hearing impairment. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 317-23	6.1	17